OBJECTIVE: Osteoporosis is associated with an impaired balance between bone resorption and formation, which in turn leads to bone loss and fractures. Many recent studies have underlined the regulatory role of microRNAs (miRNAs) in bone remodeling processes and their potential as biomarkers of osteoporosis. The purpose of this study was to prospectively examine the association of circulating miRNAs and bone biomarkers with estrogen status in women before and after oophorectomy, as well as in oophorectomized women on estrogen therapy. METHODS: In this prospective study, we included 11 women before oophorectomy and hysterectomy and at 201 ± 24 days after the surgery. Another 11 women were evaluated 508 ± 127 days after oophorectomy and hysterectomy and after an additional 203 ± 71 days of estradiol treatment. Serum miRNAs were profiled by sequencing. Estrogen status and biomarkers of bone metabolism were quantified. Bone mineral density was assessed in the lumbar spine. RESULTS: Our analysis revealed 17 miRNAs associated with estrogen levels. Of those miRNAs that were upregulated with estrogen deficiency and downregulated after estrogen therapy, miR-422a correlated with serum beta-carboxy-terminal type I collagen crosslinks (β-CTX) and procollagen 1 N-terminal propeptide (P1NP); and miR-1278 correlated with serum β-CTX, P1NP, osteocalcin, sclerostin, and Dickkopf-1(Dkk1). In contrast, we found an inverse association of miR-24-1-5p with estrogen status and a negative correlation with serum β-CTX, P1NP, osteoprotegerin, and sclerostin levels. CONCLUSION: The reported miRNAs associated with estrogen status and bone metabolism could be potential biomarkers of bone pathophysiology and would facilitate studies on the prevention of postmenopausal osteoporosis. Our findings require validation in an extended cohort.

Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University Prague Prague Czechia

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Prague Czechia

General University Hospital Prague Prague Czechia

Institute of Rheumatology Prague Czechia

Zobrazit více v PubMed

Khosla S, Oursler MJ, Monroe DG. Estrogen and the Skeleton. Trends Endocrinol Metab (2012) 23(11):576–81. doi: 10.1016/j.tem.2012.03.008 PubMed DOI PMC

Klibanski A, Adams-Campbell L, Bassford T, Blair SN, Boden SD. Osteoporosis Prevention, Diagnosis, and Therapy. JAMA (2001) 285(6):785–95. doi: 10.1001/jama.285.6.785 PubMed DOI

Hernlund E, Svedbom A, Ivergard M, Compston J. Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. Arch Osteo (2013) 8:136. doi: 10.1007/s11657-013-0136-1 PubMed DOI PMC

Huai Y, Zhang W, Chen Z, Zhao F, Wang W, Dang K, et al. . A Comprehensive Analysis of MicroRNAs in Human Osteoporosis. Front Endocrinol (2020) 11:516213. doi: 10.3389/fendo.2020.516213 PubMed DOI PMC

An JH, Ohn JH, Song JA, Yang JY, Park H, Choi HJ, et al. . Changes of MicroRNA Profile and MicroRNA-MRNA Regulatory Network in Bones of Ovariectomized Mice. J Bone Mine Res (2014) 29(3):644–56. doi: 10.1002/jbmr.2060 PubMed DOI

Yavropoulou MP, Yovos JG. The "Dark Matter" of DNA and the Regulation of Bone Metabolism: The Role of Non-Coding RNAs. J Musculos Neuro Interact (2018) 18(1):18–31. PubMed PMC

Jones TL, Esa MS, Li KHC, Krishnan SRG, Elgallab GM, Pearce MS, et al. . Osteoporosis, Fracture, Osteoarthritis & Sarcopenia: A Systematic Review of Circulating MicroRNA Association. Bone (2021) 152:116068. doi: 10.1016/j.bone.2021.116068 PubMed DOI

Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. . MiRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells (2020) 9(2):276. doi: 10.3390/cells9020276 PubMed DOI PMC

Grillari J, Makitie RE, Kocijan R, Haschka J, Vazquez DC, Semmelrock E, et al. . Circulating MiRNAs in Bone Health and Disease. Bone (2020) 145:115787. doi: 10.1016/j.bone.2020.115787 PubMed DOI

Zhao W, Shen G, Ren H, Liang, Yu X, Zhang Z, et al. . Therapeutic Potential of MicroRNAs in Osteoporosis Function by Regulating the Biology of Cells Related to Bone Homeostasis. J Cell Physiol (2018) 233(12):9191–208. doi: 10.1002/jcp.26939 PubMed DOI

Seeliger C, Karpinski K, Haug AT, Vester H, Schmitt A, Bauer JS, et al. . Five Freely Circulating MiRNAs and Bone Tissue MiRNAs Are Associated with Osteoporotic Fractures. J Bone Mine Res (2014) 29(8):1718–28. doi: 10.1002/jbmr.2175 PubMed DOI

Kocijan R, Muschitz C, Geiger E, Skalicky S, Baierl A, Dormann R, et al. . Circulating Microrna Signatures in Patients with Idiopathic and Postmenopausal Osteoporosis and Fragility Fractures. J Clin Endocrinol Metab (2016) 101(11):4125–34. doi: 10.1210/jc.2016-2365 PubMed DOI

Panach L, Mifsut D, Tarin JJ, Cano A, Garcia-Perez MA. Serum Circulating MicroRNAs as Biomarkers of Osteoporotic Fracture. Calcif Tissue Int (2015) 97(5):495–505. doi: 10.1007/s00223-015-0036-z PubMed DOI

Chen Z, Bemben MG, Bemben DA. Bone and Muscle Specific Circulating MicroRNAs in Postmenopausal Women Based on Osteoporosis and Sarcopenia Status. Bone (2019) 120:271–8. doi: 10.1016/j.bone.2018.11.001 PubMed DOI

Yavropoulou MP, Anastasilakis AD, Makras P, Tsalikakis DG, Grammatiki M, Yovos JG. Expression of MicroRNAs That Regulate Bone Turnover in the Serum of Postmenopausal Women with Low Bone Mass and Vertebral Fractures. Eur J Endocrinol (2017) 176(2):169–76. doi: 10.1530/EJE-16-0583 PubMed DOI

Sun M, Zhou X, Chen L, Huang S, Leung V, Wu N, et al. . The Regulatory Roles of MicroRNAs in Bone Remodeling and Perspectives as Biomarkers in Osteoporosis. BioMed Res Int (2016) 2016:1652417. doi: 10.1155/2016/1652417 PubMed DOI PMC

Taipaleenmaki H, Bjerre Hokland L, Chen L, Kauppinen S, Kassem M. Mechanisms in Endocrinology: Micro-RNAs: Targets for Enhancing Osteoblast Differentiation and Bone Formation. Eur J Endocrinol (2012) 166(3):359–71. doi: 10.1530/EJE-11-0646 PubMed DOI

Anastasilakis AD, Papachatzopoulos S, Makras P, Gkiomisi A, Nikolakopoulos P, Polyzos SA, et al. . The Effect of Pharmacological Cessation and Restoration of Menstrual Cycle on Bone Metabolism in Premenopausal Women with Endometriosis. Bone (2022) 158:116354. doi: 10.1016/j.bone.2022.116354 PubMed DOI

Stepan JJ, Hruskova H, Kverka M. Update on Menopausal Hormone Therapy for Fracture Prevention. Curr Osteo Rep (2019) 17(6):465–73. doi: 10.1007/s11914-019-00549-3 PubMed DOI PMC

World Medical A . World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA (2013) 310(20):2191–4. doi: 10.1001/jama.2013.281053 PubMed DOI

Martin M. Cutadapt Removes Adapter Sequences from High-Throughput Sequencing Reads. EMBnetjournal (2011) 17:10. doi: 10.14806/ej.17.1.200 DOI

Andrews S. Babraham Bioinformatics - Fastqc a Quality Control Tool for High Throughput Sequence Data. Soil (1973) 5:47–81.

Vitsios DM, Enright AJ. Chimira: Analysis of Small RNA Sequencing Data and MicroRNA Modifications. Bioinformatics (2015) 31(20):3365–7. doi: 10.1093/bioinformatics/btv380 PubMed DOI PMC

Kozomara A, Griffiths-Jones S. Mirbase: Annotating High Confidence MicroRNAs Using Deep Sequencing Data. Nucleic Acids Res (2014) 42(Database issue):D68–73. doi: 10.1093/nar/gkt1181 PubMed DOI PMC

Team RC . R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; (2021).

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, 3rd, et al. . A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med (2009) 150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006 PubMed DOI PMC

Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with Deseq2. Genome Biol (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8 PubMed DOI PMC

Brooks ME, Kristensen K, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. . Glmmtmb Balances Speed and Flexibility among Packages for Zero-Inflated Generalized Linear Mixed Modeling. R J (2017) 9(2):378–400. doi: 10.32614/RJ-2017-066 DOI

Benjamini Y, Hochberg Y. Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc (1995) 57(1):289–300.

Zeng Y, Qu X, Li H, Huang S, Wang S, Xu Q, et al. . MicroRNAa-100 Regulates Osteogenic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells by Targeting Bmpr2. FEBS Lett (2012) 586(16):2375–81. doi: 10.1016/j.febslet.2012.05.049 PubMed DOI

Cheng VK, Au PC, Tan KC, Cheung CL. MicroRNA and Human Bone Health. JBMR Plus (2019) 3(1):2–13. doi: 10.1002/jbm4.10115 PubMed DOI PMC

Weilner S, Skalicky S, Salzer B, Keider V, Wagner M, Hildner F, et al. . Differentially Circulating MiRNAs after Recent Osteoporotic Fractures Can Influence Osteogenic Differentiation. Bone (2015) 79:43–51. doi: 10.1016/j.bone.2015.05.027 PubMed DOI

Edmonston D, Wolf M. Fgf23 at the Crossroads of Phosphate, Iron Economy and Erythropoiesis. Nat Rev Nephrol (2020) 16(1):7–19. doi: 10.1038/s41581-019-0189-5 PubMed DOI

Cao Z, Moore BT, Wang Y, Peng XH, Lappe JM, Recker RR, et al. . Mir-422a as a Potential Cellular MicroRNA Biomarker for Postmenopausal Osteoporosis. PloS One (2014) 9(5):e97098. doi: 10.1371/journal.pone.0097098 PubMed DOI PMC

Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, et al. . Effect of Surgical Menopause and Estrogen Replacement on Cytokine Release from Human Blood Mononuclear Cells. Proc Natl Acad Sci USA (1991) 88(12):5134–8. doi: 10.1073/pnas.88.12.5134 PubMed DOI PMC

D'Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C, et al. . Estrogen Deficiency Increases Osteoclastogenesis up-Regulating T Cells Activity: A Key Mechanism in Osteoporosis. Bone (2008) 43(1):92–100. doi: 10.1016/j.bone.2008.02.017 PubMed DOI

Adeel S, Singh K, Vydareny KH, Kumari M, Shah E, Weitzmann MN, et al. . Bone Loss in Surgically Ovariectomized Premenopausal Women Is Associated with T Lymphocyte Activation and Thymic Hypertrophy. J Investig Med (2013) 61(8):1178–83. doi: 10.2310/JIM.0000000000000016 PubMed DOI PMC

Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, et al. . Inflammatory Markers and Incident Fracture Risk in Older Men and Women: The Health Aging and Body Composition Study. J Bone Mine Res (2007) 22(7):1088–95. doi: 10.1359/jbmr.070409 PubMed DOI

Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens Suppress Rank Ligand-Induced Osteoclast Differentiation Via a Stromal Cell Independent Mechanism Involving C-Jun Repression. Proc Natl Acad Sci USA (2000) 97(14):7829–34. doi: 10.1073/pnas.130200197 PubMed DOI PMC

Lehmann J, Thiele S, Baschant U, Rachner TD, Niehrs C, Hofbauer LC, et al. . Mice Lacking Dkk1 in T Cells Exhibit High Bone Mass and Are Protected from Estrogen-Deficiency-Induced Bone Loss. iScience (2021) 24(3):102224. doi: 10.1016/j.isci.2021.102224 PubMed DOI PMC

Tian J, Xu XJ, Shen L, Yang YP, Zhu R, Shuai B, et al. . Association of Serum Dkk-1 Levels with Beta-Catenin in Patients with Postmenopausal Osteoporosis. J Huazhong Univ Sci Tech Med Sci (2015) 35(2):212–8. doi: 10.1007/s11596-015-1413-6 PubMed DOI

Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, et al. . Regulation of Circulating Sclerostin Levels by Sex Steroids in Women and in Men. J Bone Mine Res (2011) 26(1):27–34. doi: 10.1002/jbmr.128 PubMed DOI PMC

Fujita K, Roforth MM, Demaray S, McGregor U, Kirmani S, McCready LK, et al. . Effects of Estrogen on Bone MRNA Levels of Sclerostin and Other Genes Relevant to Bone Metabolism in Postmenopausal Women. J Clin Endocrinol Metab (2014) 99(1):E81–8. doi: 10.1210/jc.2013-3249 PubMed DOI PMC

Glass DA, Bialek P, 2nd, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. . Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast Differentiation. Dev Cell (2005) 8(5):751–64. doi: 10.1016/j.devcel.2005.02.017 PubMed DOI

Anastasilakis AD, Makras P, Pikilidou M, Tournis S, Makris K, Bisbinas I, et al. . Changes of Circulating MicroRNAs in Response to Treatment with Teriparatide or Denosumab in Postmenopausal Osteoporosis. J Clin Endocrinol Metab (2018) 103(3):1206–13. doi: 10.1210/jc.2017-02406 PubMed DOI

Eriksen EF. Normal and Pathological Remodeling of Human Trabecular Bone: Three Dimensional Reconstruction of the Remodeling Sequence in Normals and in Metabolic Bone Disease. Endocr Rev (1986) 7(4):379–408. doi: 10.1210/edrv-7-4-379 PubMed DOI

Hannon R, Blumsohn A, Naylor K, Eastell R. Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological Variability. J Bone Mine Res (1998) 13(7):1124–33. doi: 10.1359/jbmr.1998.13.7.1124 PubMed DOI

Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women. J Clin Endocrinol Metab (2010) 95(4):1991–7. doi: 10.1210/jc.2009-2283 PubMed DOI PMC

Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of Serum Sclerostin in Healthy Pre- and Postmenopausal Women. J Bone Mine Res (2011) 26(12):2812–22. doi: 10.1002/jbmr.479 PubMed DOI

O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, et al. . Control of Bone Mass and Remodeling by Pth Receptor Signaling in Osteocytes. PloS One (2008) 3(8):e2942. doi: 10.1371/journal.pone.0002942 PubMed DOI PMC

Ahmed SF, Fouda N, Abbas AA. Serum Dickkopf-1 Level in Postmenopausal Females: Correlation with Bone Mineral Density and Serum Biochemical Markers. J Osteo (2013) 2013:460210. doi: 10.1155/2013/460210 PubMed DOI PMC

Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al. . Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis. J Bone Mine Res (1999) 14(4):518–27. doi: 10.1359/jbmr.1999.14.4.518 PubMed DOI

Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum Levels of Osteoprotegerin Increase with Age in a Healthy Adult Population. Bone (2003) 32(6):681–6. doi: 10.1016/S8756-3282(03)00090-5 PubMed DOI

Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, et al. . The Changes in Circulating Osteoprotegerin after Hormone Therapy in Postmenopausal Women and Their Relationship with Oestrogen Responsiveness on Bone. Clin Endocrinol (Oxf) (2005) 62(3):349–53. doi: 10.1111/j.1365-2265.2005.02221.x PubMed DOI

Chung YE, Lee SH, Lee SY, Kim SY, Kim HH, Mirza FS, et al. . Long-Term Treatment with Raloxifene, but Not Bisphosphonates, Reduces Circulating Sclerostin Levels in Postmenopausal Women. Osteo Int (2012) 23(4):1235–43. doi: 10.1007/s00198-011-1675-1 PubMed DOI

Roth MJ, Moorehead RA. The Mir-200 Family in Normal Mammary Gland Development. BMC Dev Biol (2021) 21(1):12. doi: 10.1186/s12861-021-00243-7 PubMed DOI PMC

Fontana A, Barbano R, Dama E, Pasculli B, Rendina M, Morritti MG, et al. . Combined Analysis of Mir-200 Family and Its Significance for Breast Cancer. Sci Rep (2021) 11(1):2980. doi: 10.1038/s41598-021-82286-1 PubMed DOI PMC

Kerschan-Schindl K, Hackl M, Boschitsch E, Foger-Samwald U, Nagele O, Skalicky S, et al. . Diagnostic Performance of a Panel of MiRNAs (Osteomir) for Osteoporosis in a Cohort of Postmenopausal Women. Calcif Tissue Int (2021) 108(6):725–37. doi: 10.1007/s00223-020-00802-3 PubMed DOI PMC

Straub RH. The Complex Role of Estrogens in Inflammation. Endocr Rev (2007) 28(5):521–74. doi: 10.1210/er.2007-0001 PubMed DOI

Faubion L, White TA, Peterson BJ, Geske JR, LeBrasseur NK, Schafer MJ, et al. . Effect of Menopausal Hormone Therapy on Proteins Associated with Senescence and Inflammation. Physiol Rep (2020) 8(16):e14535. doi: 10.14814/phy2.14535 PubMed DOI PMC

Lisse TS, Chun RF, Rieger S, Adams JS, Hewison M. Vitamin D Activation of Functionally Distinct Regulatory MiRNAs in Primary Human Osteoblasts. J Bone Mine Res (2013) 28(6):1478–88. doi: 10.1002/jbmr.1882 PubMed DOI PMC

Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, et al. . Chronic Elevation of Parathyroid Hormone in Mice Reduces Expression of Sclerostin by Osteocytes: A Novel Mechanism for Hormonal Control of Osteoblastogenesis. Endocrinology (2005) 146(11):4577–83. doi: 10.1210/en.2005-0239 PubMed DOI

Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ. Effect of Supplemental Vitamin D and Calcium on Serum Sclerostin Levels. Eur J Endocrinol (2014) 170(4):645–50. doi: 10.1530/EJE-13-0862 PubMed DOI PMC

Acibucu F, Dokmetas HS, Acibucu DO, Kilicli F, Aydemir M, Cakmak E. Effect of Vitamin D Treatment on Serum Sclerostin Level. Exp Clin Endocrinol Diabetes (2017) 125(9):634–7. doi: 10.1055/s-0035-1559790 PubMed DOI

Randolph JF, Jr, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ. Change in Estradiol and Follicle-Stimulating Hormone across the Early Menopausal Transition: Effects of Ethnicity and Age. J Clin Endocrinol Metab (2004) 89(4):1555–61. doi: 10.1210/jc.2003-031183 PubMed DOI

Feurer E, Kan C, Croset M, Sornay-Rendu E, Chapurlat R. Lack of Association between Select Circulating MiRNAs and Bone Mass, Turnover, and Fractures: Data from the Ofely Cohort. J Bone Mine Res (2019) 34(6):1074–85. doi: 10.1002/jbmr.3685 PubMed DOI

You L, Pan L, Chen L, Gu W, Chen J. Mir-27a Is Essential for the Shift from Osteogenic Differentiation to Adipogenic Differentiation of Mesenchymal Stem Cells in Postmenopausal Osteoporosis. Cell Physiol Biochem (2016) 39(1):253–65. doi: 10.1159/000445621 PubMed DOI